Target Name: CDC20-DT
NCBI ID: G105378687
Review Report on CDC20-DT Target / Biomarker Content of Review Report on CDC20-DT Target / Biomarker
CDC20-DT
Other Name(s): CDC20 divergent transcript, transcript variant X4 | CDC20-DT variant X2 | CDC20-DT variant X4 | CDC20 divergent transcript | CDC20-DT variant X3 | CDC20-DT variant X5 | CDC20 divergent transcript, transcript variant X3 | CDC20 divergent transcript, transcript variant X2 | CDC20 divergent transcript, transcript variant X5

A Promising Potential Drug Target: CDC20-DT, a Variant of the CD20 Transcript in Chronic Myeloid Leukemia

Introduction

Chronic Myeloid Leukemia (CML) is a type of cancer that affects the bone marrow, where white blood cells called leukemia cells overgrow. The most common cause of CML is the BCR-ABL fusion gene, which results in the production of a Philadelphia with chromosome a translocation of the breakpoint gene (TEL-AML-RET) to the BCR gene. This fusion gene creates a BCR-Abl tyrosine kinase that promotes the proliferation of leukemia cells. Although there are several treatment options available for CML, the lack of effective targeting agents remains a major challenge.

CD20 is a protein that is expressed in various types of hematopoietic cells, including B cells, and is known as the B-cell antigen receptor (BCR) 130. It is a potential drug target for CML because BCR-ABL fusion genes express high levels of CD20. Therefore, targeting the expression and function of CD20 could be a promising strategy for the development of new treatments for CML.

CD20 Variants in CML

CD20 has four splice variants, which are designated as CDC20-DT, CDC20-DN, CDC20-DS, and CDC20-DD. These variants differ in the last exon, which is involved in the formation of a glycylated form of the protein. The splice variants also differ in the presence or absence of a splice acceptor protein, which is necessary for the production of functional RNA.

CDC20-DT is the most abundant splice variant and is expressed in most types of hematopoietic cells, including B cells. It is a glycylated form of CD20 and has been shown to be a good predictor of response to AML therapies.

CDC20-DN is a less abundant splice variant that is expressed in a subset of hematopoietic cells, including natural killer cells and some types of progenitor cells. It is a non-glycylated form of CD20 and has been shown to have a different expression pattern than CDC20-DT.

CDC20-DS is a rare splice variant that is expressed in only a few types of hematopoietic cells, including stem cells and some types of progenitor cells. It is a non-glycylated form of CD20 and has been shown to have a different expression pattern than CDC20-DT and -DN.

CDC20-DD is a rare splice variant that is expressed in only a few types of hematopoietic cells, including stem cells and some types of progenitor cells. It is a non-glycylated form of CD20 and has been shown to have a different expression pattern than CDC20-DT and -DN.

CD20 Expression and Function

CD20 is a glycylated form of the protein that is expressed in various types of hematopoietic cells, including B cells, natural killer cells, and some progenitor cells. It is a B cell antigen receptor (BCR) 130 and is involved in the development and maintenance of hematopoietic stem cells (HSCs) and natural killer cells (NK cells).

CD20 has been shown to play a role in the regulation of hematopoietic stem cell (HSC) proliferation and differentiation. It has been shown to be involved in the

Protein Name: CDC20 Divergent Transcript

The "CDC20-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC20-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2